Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.
about
Idiosyncratic adverse drug reactions: current conceptsLiver safety assessment: required data elements and best practices for data collection and standardization in clinical trialsLiver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting systemA proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database.Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational studyOngoing challenges in pharmacovigilance.Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges.Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk.Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials DatabaseDrug safety sciences and the bottleneck in drug development.Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future.Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.Hepatotoxicity of New Oral Anticoagulants (NOACs).Acute Liver Failure after Initiation of Rivaroxaban: A Case Report and Review of the Literature.Recent advances in biomarkers and therapeutic interventions for hepatic drug safety - false dawn or new horizon?Current challenges and controversies in drug-induced liver injury.Regulatory forum opinion piece: the role of the toxicologic pathologist in the postgenomic era: challenges and opportunities.Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial.CSH guidelines for the diagnosis and treatment of drug-induced liver injuryAnti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law.The clinical liver safety assessment best practices workshop: rationale, goals, accomplishments and the future.In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials.Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients.Portal vein thrombosis in patients with cirrhosis: underdiagnosis and undertreatment?
P2860
Q26824391-65466EFB-3E3E-4138-B582-5F1F1D5BEE56Q27006916-0697DE81-04EC-4920-B6D9-BBBB8FF0005DQ28257188-2344B60A-4537-48B7-B5DB-4F4CE6800642Q30585177-E7AA6A53-D472-44E7-B197-23E4390833C5Q30852962-BFD03249-D72A-4030-B784-90558424051FQ33424900-AE22B52C-8D62-4899-85F1-22391721BD8EQ33805921-D1FA6A65-61AE-407F-AEDA-318A1C671633Q34417013-F154D1DC-6A00-4F99-A5C7-7273AD60B56DQ34417044-6C1F567B-99A4-4311-8B79-56A8399DCC51Q35819331-E7BCC889-6ABC-4F90-BCF3-F8E99B533F86Q36171663-D98777E5-480D-4B03-B662-C8B5ADF1D856Q37877129-BF0CAB9D-9849-4238-B59B-C835AC3D8A9DQ38032729-8807463D-921C-4351-9791-535044F5B199Q38430712-816385C6-ED90-4AA3-9C4B-E683B93C2AF9Q38542198-8AD90F8A-A850-4D11-9B1D-FCC899B64A1FQ38647192-9C3AE78D-3AC1-4E56-A966-9F0A26969CDDQ38753644-34E91A09-9DCA-4649-9A42-C368B668A73EQ39523252-C4221643-6F4B-4A61-B90B-7A4E98DB093BQ39617511-08E7651E-8B45-4B9B-883B-41D4F7A16C2CQ40187951-B52B2D63-6C3C-4284-B1E5-7965ED13DDB5Q41513917-E9E446E8-4378-4C0F-BE88-35A96E2AE96FQ42354312-EA9EFEB4-E278-4D24-A41D-5BF2A70D29E6Q46149018-1B578DAF-508F-4ED9-9FF5-997FC1F23536Q47571376-14B449A0-CE6E-441A-B7D8-062AB298CFC6Q47667702-A7AD1BBA-5579-44B7-ABC5-BD59CDFC3C71Q51109085-0F6C83DC-ED67-4C8C-B8DE-B366D6E24400Q53783646-1A364D94-C744-46E2-ADCE-8D11DA473818
P2860
Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Evaluation of drug-induced ser ...... p or knee replacement surgery.
@ast
Evaluation of drug-induced ser ...... p or knee replacement surgery.
@en
type
label
Evaluation of drug-induced ser ...... p or knee replacement surgery.
@ast
Evaluation of drug-induced ser ...... p or knee replacement surgery.
@en
prefLabel
Evaluation of drug-induced ser ...... p or knee replacement surgery.
@ast
Evaluation of drug-induced ser ...... p or knee replacement surgery.
@en
P2093
P2860
P1433
P1476
Evaluation of drug-induced ser ...... p or knee replacement surgery.
@en
P2093
Dominique Larrey
Gary Peters
Mehul Desai
Paul B Watkins
Willis Maddrey
Yves Horsmans
P2860
P304
P356
10.2165/11586600-000000000-00000
P577
2011-03-01T00:00:00Z
P6179
1038383255